HIV combo therapy suppresses HBV in some patients

04/29/2013 | MedPage Today (free registration)

Tenofovir and emtricitabine can suppress hepatitis B among patients in the immune-tolerant stage, according to a study presented at a liver disease research meeting in Europe. Researchers tracked 126 HBV patients and found that 76% of those who took the tenofovir-emtricitabine combination for four years experienced viral suppression compared with 55% of those who received tenofovir alone. Few patients, however, regained their immune response to the pathogen, and among participants who stopped taking the drugs, viral loads returned to pre-study levels.

View Full Article in:

MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ